Richard A. Larson to Cytogenetics
This is a "connection" page, showing publications Richard A. Larson has written about Cytogenetics.
Connection Strength
0.368
-
Therapy-related myeloid neoplasms in 109 patients after radiation monotherapy. Blood Adv. 2021 10 26; 5(20):4140-4148.
Score: 0.208
-
High early death rates, treatment resistance, and short survival of Black adolescents and young adults with AML. Blood Adv. 2022 10 11; 6(19):5570-5581.
Score: 0.056
-
Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol. 2012 Dec 20; 30(36):4515-23.
Score: 0.028
-
FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood. 2010 Nov 04; 116(18):3622-6.
Score: 0.024
-
FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood. 2008 Feb 01; 111(3):1552-9.
Score: 0.020
-
Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood. 2007 Oct 01; 110(7):2309-15.
Score: 0.019
-
Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases. Proc Natl Acad Sci U S A. 1993 Jun 15; 90(12):5484-8.
Score: 0.007
-
Interphase cytogenetic analysis detects minimal residual disease in a case of acute lymphoblastic leukemia and resolves the question of origin of relapse after allogeneic bone marrow transplantation. Blood. 1991 Mar 01; 77(5):1087-91.
Score: 0.006